Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900487 | 1.00 | CYP19A1 (0.70) | CYP19A1SMN1; SMN2NR1I2ALDH1A1NR3C1 | |
| SCHEMBL1780129 | 0.88 | CYP17A1 (0.55) | CYP19A1SMN1; SMN2ALDH1A1NR3C1PGR | |
| SCHEMBL1780130 | 0.88 | CYP17A1 (0.55) | CYP19A1SMN1; SMN2ALDH1A1NR3C1PGR | |
| SCHEMBL10380895 | 0.85 | CYP19A1 (0.72) | CYP19A1SMN1; SMN2NR1I2ALDH1A1NR3C1 | |
| SCHEMBL10380893 | 0.85 | CYP19A1 (0.72) | CYP19A1SMN1; SMN2NR1I2ALDH1A1NR3C1 | |
| SCHEMBL10380894 | 0.85 | CYP19A1 (0.72) | CYP19A1SMN1; SMN2NR1I2ALDH1A1NR3C1 | |
| SCHEMBL5432268 | 0.83 | CYP19A1 (0.68) | CYP19A1SMN1; SMN2NR1I2ALDH1A1NR3C1 | |
| SCHEMBL5432264 | 0.83 | CYP19A1 (0.68) | CYP19A1SMN1; SMN2NR1I2ALDH1A1NR3C1 | |
| SCHEMBL7520550 | 0.83 | CYP19A1 (0.64) | CYP19A1SMN1; SMN2NR1I2ALDH1A1NR3C1 | |
| SCHEMBL42712 | 0.82 | CYP19A1 (1.00) | CYP19A1SMN1; SMN2ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124587-A1 | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS | AUERBACH ALAN H | 2009-05-14 | — | — | US | claimed |
| WO-2009009132-A1 | USE OF 17ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITORS FOR THE TREATMENT OF CANCER | COUGAR BIOTECHNOLOGY, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| US-11974977-B2 | Composition and uses for influencing hair growth | LUCOLAS—M.D. LTD (GB) | 2024-05-07 | — | — | US | disclosed |
| US-11324711-B2 | Composition and uses for influencing hair growth | S.W. PATENTVERWERTUNGS LIMITED (GB) | 2022-05-10 | — | — | US | disclosed |
| US-20220133749-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | JANSSEN ONCOLOGY INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210290579-A1 | COMPOSITION AND USES FOR INFLUENCING HAIR GROWTH | LUCOLAS M D LTD (GB) | 2021-09-23 | — | — | US | disclosed |
| US-11052059-B2 | Composition and uses for influencing hair growth | LUCOLAS - M.D. LTD (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3804730-A1 | COMPOSITIONS FOR TREATING CANCER | Janssen Oncology, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200237785-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | JANSSEN ONCOLOGY INC (US) | 2020-07-30 | — | — | US | disclosed |
| US-10702589-B2 | Compositions and methods of treating neurological disorder and stress-induced conditions | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702540-B2 | Methods and compositions for treating cancer | JANSSEN ONCOLOGY, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2008024484-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | COUGAR BIOTECHNOLOGY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070148123-A1 | Substances and agents for positively influencing collagen | WIELAND HEINRICH | 2007-06-28 | — | — | US | disclosed |
| US-20040241087-A1 | Aromatase marking | MEDICAL DISCOVERIES, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040018991-A1 | Topical treatment for mastalgia | MDI ONCOLOGY, INC. | 2004-01-29 | — | — | US | disclosed |
| EP-0633893-B1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BTG INT LTD (GB) | 1999-11-24 | — | — | EP | disclosed |
| US-5618807-A | Method for preparing 17-substituted steroids useful in cancer treatment | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-04-08 | — | — | US | disclosed |
| US-5604213-A | STEROID DEPENDENT CANCERS SUCH AS PROSTATE AND BREAST CANCER | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-02-18 | — | — | US | disclosed |
| EP-0633893-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD (GB) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993020097-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124587-A1 | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B11 | CYP19A1 12/4885SMN1; SMN2 4281/4885NR1I2 473/4885 |
| US-10702540-B2 | Methods and compositions for treating cancer | CYP17A1, HSD17B7, HSD17B11 | CYP19A1 17/4885SMN1; SMN2 4133/4885NR1I2 671/4885 |
| US-20220133749-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CYP17A1, HSD17B7, HSD17B11 | CYP19A1 17/4885SMN1; SMN2 4133/4885NR1I2 671/4885 |
| US-20200237785-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CYP17A1, HSD17B7, HSD17B11 | CYP19A1 17/4885SMN1; SMN2 4133/4885NR1I2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.